Indolent Lymphoma Commission

Indolent lymphomas include follicular and non-follicular lymphomas belonging to the group of Non-Hodgkin’s Lymphomas (a family of tumors that involve the lymphatic system, the cells and tissues that have the task of defending the organism from external agents and diseases and guaranteeing proper circulation of fluids in the body).
Indolent B lymphomas may have an initial asymptomatic phase that does not require an immediate treatment. However, they tend to recur over the years, so they require repeated treatments.
The prognosis is clearly improving, thanks above all to the new biological drugs including
, in particular, anti-CD20 monoclonal antibodies. 

Linfomi Indolenti

The goals of the Indolent Lymphoma Commission are the following: 

  • Conduct nationwide phase III studies, also with the support of AIFA (Agenzia Italiana del Farmaco, Italian Drug Agency), aimed at comparing different strategies in the standard therapy of follicular lymphoma for diagnosis and relapse; 
  • Approve the study proposals for patients with non-follicular Indolent Lymphoma at diagnosis and disease relapse; 
  • Propose phase II studies with drugs or combinations of innovative drugs, in groups of patients selected for age or for specific clinical features, including asymptomatic patients; 
  • Approve the study proposals aimed at identifying factors of prognostic relevance to the diagnosis; 
  • Perform retrospective analyzes aimed at better understanding the role of some particular therapeutic practices; 
  • Collaborate with the Biological Studies Commission for integrated analyzes on the clinical prognostic significance of biological parameters, such as the minimal residual disease; 
  • Collaborate with the Imaging and Radioimmunotherapy Commission for retrospective and prospective analyzes on the prognostic significance of instrumental investigations such as PET, as well as in perspective with other FIL Commissions (Radiotherapy and Pathologists) for potential future studies, in particular on transformed or histologically more aggressive lymphomas (3b) 
  • Evaluate the pathogenetic and therapeutic relevance of the association infectious agents-lymphoma in some forms of non-follicular Indolent Lymphoma; 
  • Interact with national and international study groups for possible collaborative studies. 

 

The Indolent Lymphoma Commission is coordinated by Dr. Stefano Luminari, haematologist at AUSL IRCCS Arcispedale Santa Maria Nuova of Reggio Emilia.

Luminari